CELSION CORP (CLSN)

US15117N6022 - Common Stock

1.96  0 (0%)

After market: 1.96 0 (0%)

Fundamental Rating

1

Taking everything into account, CLSN scores 1 out of 10 in our fundamental rating. CLSN was compared to 588 industry peers in the Biotechnology industry. CLSN may be in some trouble as it scores bad on both profitability and health. CLSN has a expensive valuation and it also scores bad on growth.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CLSN has reported negative net income.
In the past 5 years CLSN always reported negative net income.
In the past 5 years CLSN always reported negative operating cash flow.

1.2 Ratios

Industry RankSector Rank
ROA -40.03%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Operating Margin and Gross Margin are not available for CLSN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) -5229.82%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

CLSN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CLSN has been reduced compared to 1 year ago.
CLSN has a better debt/assets ratio than last year.

2.2 Solvency

CLSN has an Altman-Z score of -7.47. This is a bad value and indicates that CLSN is not financially healthy and even has some risk of bankruptcy.
CLSN has a Debt/Equity ratio of 0.13. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Altman-Z -7.47
ROIC/WACCN/A
WACC10.77%

2.3 Liquidity

CLSN has a Current Ratio of 6.52. This indicates that CLSN is financially healthy and has no problem in meeting its short term obligations.
A Quick Ratio of 6.52 indicates that CLSN has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 6.52
Quick Ratio 6.52

More info and screens

0

3. Growth

3.1 Past

CLSN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -35.02%.
CLSN shows a decrease in Revenue. In the last year, the revenue decreased by -2.91%.
EPS 1Y (TTM)-35.02%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q3.33%
Revenue 1Y (TTM)-2.91%
Revenue growth 3Y0%
Revenue growth 5Y0%
Revenue growth Q2Q0%

3.2 Future

CLSN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 5.59% yearly.
Based on estimates for the next years, CLSN will show a very negative growth in Revenue. The Revenue will decrease by -22.71% on average per year.
EPS Next Y21.32%
EPS Next 2Y11.03%
EPS Next 3Y14.57%
EPS Next 5Y5.59%
Revenue Next Year0%
Revenue Next 2Y-29.29%
Revenue Next 3Y-20.63%
Revenue Next 5Y-22.71%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CLSN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CLSN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 1.03

4.3 Compensation for Growth

A more expensive valuation may be justified as CLSN's earnings are expected to grow with 14.57% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y11.03%
EPS Next 3Y14.57%

More info and screens

0

5. Dividend

5.1 Amount

CLSN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CELSION CORP

NASDAQ:CLSN (9/20/2022, 7:01:31 PM)

After market: 1.96 0 (0%)

1.96

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap13.91M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.03%
ROE N/A
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) -5229.82%
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 6.52
Quick Ratio 6.52
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-35.02%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y21.32%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-2.91%
Revenue growth 3Y0%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y